Table 1.
Adverse events * | Topiramate (N = 896) N (%) |
Paresthesia/numbness | 116 (12.9) |
Nausea/vomiting | 56 (6.2) |
Cognitive impairment | 48 (5.4) |
Headache | 46 (5.1) |
Dizziness | 45(5.0) |
Sedation/drowsiness | 44 (4.9) |
Fatigue | 38 (4.2) |
Decreased appetite | 24 (2.7) |
Frequent peristalsis | 20 (2.2) |
Somnolence | 19 (2.1) |
Blurred vision | 18 (2.0) |
Slow memory | 16 (1.8) |
Lack of concentration | 11 (1.2) |
Influenza-like-symptoms | 10 (1.1) |
Panic/anxiety | 9 (1.0) |
Dysgeusia | 8 (0.9) |
Dry mouth | 8 |
Nervousness | 7 (0.8) |
Rash | 7 |
Ataxia | 7 |
Insomnia | 7 |
Constipation | 7 |
Reduced libido | 5 (0.6) |
Memory concerns | 5 |
Dyspepsia | 5 |
Unwanted weight loss | 4 (0.4) |
Increased thirst | 4 |
Word-finding difficulty | 4 |
Impaired concentration | 4 |
Tremor | 4 |
Itching | 4 |
Sweating | 3 (0.3) |
Confusion | 3 |
Slowed thinking | 3 |
Psychosis | 3 |
Slurred speech | 3 |
Increased salivation | 3 |
Sleep disturbance | 3 |
Backache | 3 |
Increased appetite | 2 (0.2) |
Gastrointestinal disturbances | 2 |
Agitation | 2 |
Cold sensitivity | 2 |
Worsening of symptoms | 2 |
Increased libido | 2 |
Amenorrhea | 1 (0.1) |
Hematuria | 1 |
Dysuria | 1 |
Urticaria | 1 |
Increased suicidality | 1 |
Glaucoma | 1 |
Water retention | 1 |
Delirium | 1 |
Grand mal seizures | 1 |
(*) From the studies reviewed only